Form 4: Milestone Pharmaceuticals Director Lisa M. Giles Acquires Stock Options
SEC Form 4 Filing
Lisa M. Giles, a director of Milestone Pharmaceuticals Inc., acquired stock options for 40,000 common shares on August 28, 2024.
Summary
- On August 28, 2024, Lisa M. Giles, a director at Milestone Pharmaceuticals Inc., acquired stock options for 40,000 common shares.
- The exercise price of these options is $1.45 per share.
- The options vest in twelve equal monthly installments starting September 28, 2024, and will be fully vested by the date of the next annual meeting of stockholders, contingent upon continued service.
- The options expire on August 28, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of stock option grants to a director, which is a common practice.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 08/28/2024 | Date of transaction: Lisa M. Giles acquired stock options. |
| 08/28/2024 | Stock option exercise price is $1.45. |
| 09/28/2024 | Vesting of stock options begins in twelve equal monthly installments. |
| 08/28/2034 | Expiration date of the stock options. |
| 08/29/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.